EGFR (K728A)
Sign in to save this workspaceEGFR · Variant type: point · HGVS: p.K728A
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Osimertinib | 100.0% | 0.0% | 97.24 |
| 2 | Neratinib | 100.0% | 0.0% | 93.18 |
| 3 | Mobocertinib | 100.0% | 0.0% | 97.22 |
| 4 | Lazertinib | 100.0% | 0.0% | 97.47 |
| 5 | Erlotinib | 100.0% | 0.0% | 99.75 |
| 6 | Canertinib | 100.0% | 0.0% | 96.49 |
| 7 | Vandetanib | 100.0% | 0.0% | 95.74 |
| 8 | Pralsetinib | 100.0% | 0.0% | 93.43 |
| 9 | Ibrutinib | 99.5% | 0.5% | 94.74 |
| 10 | Dacomitinib | 99.2% | 0.8% | 97.99 |
| 11 | Defactinib | 98.4% | 1.6% | 92.68 |
| 12 | Alpelisib | 98.4% | 1.6% | 97.22 |
| 13 | Lapatinib | 98.2% | 1.8% | 99.25 |
| 14 | Fostamatinib | 98.2% | 1.8% | 96.74 |
| 15 | Brigatinib | 97.3% | 2.7% | 82.96 |
| 16 | Zanubrutinib | 95.4% | 4.6% | 98.24 |
| 17 | Pacritinib | 92.4% | 7.6% | 88.64 |
| 18 | Gilteritinib | 86.4% | 13.6% | 88.97 |
| 19 | Alectinib | 86.0% | 14.0% | 95.49 |
| 20 | Pemigatinib | 74.4% | 25.6% | 98.23 |
| 21 | Pexidartinib | 59.5% | 40.5% | 99.49 |
| 22 | Fedratinib | 59.3% | 40.8% | 96.21 |
| 23 | Avapritinib | 53.4% | 46.6% | 97.73 |
| 24 | Pirtobrutinib | 46.9% | 53.1% | 99.49 |
| 25 | Apatinib | 46.8% | 53.2% | 97.73 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Osimertinib | 100.0% | 99.1% | +0.9% |
| Neratinib | 100.0% | 100.0% | +0.0% |
| Mobocertinib | 100.0% | 100.0% | +0.0% |
| Lazertinib | 100.0% | 100.0% | +0.0% |
| Erlotinib | 100.0% | 99.4% | +0.6% |
| Canertinib | 100.0% | 98.4% | +1.6% |
| Vandetanib | 100.0% | 99.3% | +0.7% |
| Pralsetinib | 100.0% | 99.1% | +0.9% |
| Ibrutinib | 99.5% | 99.3% | +0.1% |
| Dacomitinib | 99.2% | 99.8% | -0.6% |
| Defactinib | 98.4% | 94.6% | +3.9% |
| Alpelisib | 98.4% | — | — |
| Lapatinib | 98.2% | 99.2% | -1.0% |
| Fostamatinib | 98.2% | 97.8% | +0.4% |
| Brigatinib | 97.3% | 98.5% | -1.2% |
| Zanubrutinib | 95.4% | 88.2% | +7.2% |
| Pacritinib | 92.4% | — | — |
| Gilteritinib | 86.4% | 91.0% | -4.7% |
| Alectinib | 86.0% | — | — |
| Pemigatinib | 74.4% | — | — |
| Pexidartinib | 59.5% | — | — |
| Fedratinib | 59.3% | — | — |
| Avapritinib | 53.4% | — | — |
| Pirtobrutinib | 46.9% | — | — |
| Apatinib | 46.8% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_lung | Lung | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 16.1ms